Research shows that low doses of a class of cancer drugs called lysine deacetylase inhibitors have protective properties against the development of type 1 diabetes.

The researchers reviewed the effect of the drugs and found incidence of type 1 diabetes was reduced by 45% by givinostat and 38% by vorinostat. In addition, pancreatic insulin content doubled compared with untreated mice.

Click here to read the full article.